{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T01:56:17Z","timestamp":1794707777044,"version":"4.9.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T00:00:00Z","timestamp":1480291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1038\/leu.2016.360","type":"journal-article","created":{"date-parts":[[2016,11,28]],"date-time":"2016-11-28T07:44:17Z","timestamp":1480319057000},"page":"1108-1116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":240,"title":["Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia"],"prefix":"10.1038","volume":"31","author":[{"given":"M","family":"Ilander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Olsson-Str\u00f6mberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Schlums","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Br\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"L\u00e4hteenm\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Kasanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Koskenvesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"S\u00f6derlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"H\u00f6glund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Markev\u00e4rn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Sj\u00e4lander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Lotfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Dreimane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"L\u00fcbking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Bj\u00f6reman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Stenke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Ohm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Gedde-Dahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5589-3622","authenticated-orcid":false,"given":"H","family":"Ehrencrona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Koskela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Saussele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F-X","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Porkka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Hjorth-Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y T","family":"Bryceson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Mustjoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,28]]},"reference":[{"key":"BFleu2016360_CR1","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1038\/leu.2009.38","volume":"23","author":"A Hochhaus","year":"2009","unstructured":"Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054\u20131061.","journal-title":"Leukemia"},{"key":"BFleu2016360_CR2","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260\u20132270.","journal-title":"N Engl J Med"},{"key":"BFleu2016360_CR3","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251\u20132259.","journal-title":"N Engl J Med"},{"key":"BFleu2016360_CR4","doi-asserted-by":"crossref","unstructured":"Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF et al. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry. Leukemia 2016; e-pub ahead of print 23 September 2016; doi:10.1038\/leu.2016.246.","DOI":"10.1038\/leu.2016.246"},{"key":"BFleu2016360_CR5","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","volume":"101","author":"R Bhatia","year":"2003","unstructured":"Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101: 4701\u20134707.","journal-title":"Blood"},{"key":"BFleu2016360_CR6","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M, Casado LF, Garcia-Gutierrez V, Hochhaus A et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia 2016; 30: 1648\u20131671.","journal-title":"Leukemia"},{"key":"BFleu2016360_CR7","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1200\/JCO.2011.34.7146","volume":"29","author":"M Bjorkholm","year":"2011","unstructured":"Bjorkholm M, Ohm L, Eloranta S, Derolf A, Hultcrantz M, Sjoberg J et al. Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008. J Clin Oncol 2011; 29: 2514\u20132520.","journal-title":"J Clin Oncol"},{"key":"BFleu2016360_CR8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11: 1029\u20131035.","journal-title":"Lancet Oncol"},{"key":"BFleu2016360_CR9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","volume":"122","author":"DM Ross","year":"2013","unstructured":"Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122: 515\u2013522.","journal-title":"Blood"},{"key":"BFleu2016360_CR10","doi-asserted-by":"crossref","unstructured":"Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A et al. Long-term follow-up of the french stop imatinib (STIM1) study in patients with chronic myeloid leukemia. J Clin Oncol 2016; e-pub ahead of print 31 October 2016; doi:10.1200\/JCO.2016.68.2914.","DOI":"10.1200\/JCO.2016.68.2914"},{"key":"BFleu2016360_CR11","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","volume":"2","author":"J Imagawa","year":"2015","unstructured":"Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2015; 2: e528\u2013e535.","journal-title":"Lancet Haematol"},{"key":"BFleu2016360_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ . Index for rating diagnostic tests. Cancer 1950; 3: 32\u201335.","journal-title":"Cancer"},{"key":"BFleu2016360_CR13","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1002\/ijc.25233","volume":"127","author":"J Salih","year":"2010","unstructured":"Salih J, Hilpert J, Placke T, Grunebach F, Steinle A, Salih HR et al. The BCR\/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. Int J Cancer 2010; 127: 2119\u20132128.","journal-title":"Int J Cancer"},{"key":"BFleu2016360_CR14","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1182\/blood-2007-04-084814","volume":"111","author":"AE Schade","year":"2008","unstructured":"Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood 2008; 111: 1366\u20131377.","journal-title":"Blood"},{"key":"BFleu2016360_CR15","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1182\/blood-2004-07-2527","volume":"105","author":"R Seggewiss","year":"2005","unstructured":"Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005; 105: 2473\u20132479.","journal-title":"Blood"},{"key":"BFleu2016360_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109: 58\u201360.","journal-title":"Blood"},{"key":"BFleu2016360_CR17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.blre.2005.10.001","volume":"20","author":"SS Farag","year":"2006","unstructured":"Farag SS, Caligiuri MA . Human natural killer cell development and biology. Blood Rev 2006; 20: 123\u2013137.","journal-title":"Blood Rev"},{"key":"BFleu2016360_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00262-016-1803-z","volume":"65","author":"H Kared","year":"2016","unstructured":"Kared H, Martelli S, Ng TP, Pender SL, Larbi A . CD57 in human natural killer cells and T-lymphocytes. Cancer Immunol Immunother 2016; 65: 441\u2013452.","journal-title":"Cancer Immunol Immunother"},{"key":"BFleu2016360_CR19","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S1471-4906(01)02060-9","volume":"22","author":"MA Cooper","year":"2001","unstructured":"Cooper MA, Fehniger TA, Caligiuri MA . The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633\u2013640.","journal-title":"Trends Immunol"},{"key":"BFleu2016360_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.immuni.2015.02.008","volume":"42","author":"H Schlums","year":"2015","unstructured":"Schlums H, Cichocki F, Tesi B, Theorell J, Beziat V, Holmes TD et al. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 2015; 42: 443\u2013456.","journal-title":"Immunity"},{"key":"BFleu2016360_CR21","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.immuni.2015.02.013","volume":"42","author":"J Lee","year":"2015","unstructured":"Lee J, Zhang T, Hwang I, Kim A, Nitschke L, Kim M et al. Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. Immunity 2015; 42: 431\u2013442.","journal-title":"Immunity"},{"key":"BFleu2016360_CR22","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/sj.leu.2404499","volume":"21","author":"B Grzywacz","year":"2007","unstructured":"Grzywacz B, Kataria N, Verneris MR . CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia 2007; 21: 356\u2013359.","journal-title":"Leukemia"},{"key":"BFleu2016360_CR23","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1084\/jem.184.2.579","volume":"184","author":"LM Zheng","year":"1996","unstructured":"Zheng LM, Ojcius DM, Garaud F, Roth C, Maxwell E, Li Z et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 1996; 184: 579\u2013584.","journal-title":"J Exp Med"},{"key":"BFleu2016360_CR24","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3324\/haematol.2013.094045","volume":"99","author":"M Baccarani","year":"2014","unstructured":"Baccarani M, Efficace F, Rosti G . Moving towards patient-centered decision-making in chronic myeloid leukemia: assessment of quality of life and symptom burden. Haematologica 2014; 99: 205\u2013208.","journal-title":"Haematologica"},{"key":"BFleu2016360_CR25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","volume":"128","author":"TP Hughes","year":"2016","unstructured":"Hughes TP, Ross DM . Moving treatment-free remission into mainstream clinical practice in CML. Blood 2016; 128: 17\u201323.","journal-title":"Blood"},{"key":"BFleu2016360_CR26","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/leu.2016.115","volume":"30","author":"S Saussele","year":"2016","unstructured":"Saussele S, Richter J, Hochhaus A, Mahon FX . The concept of treatment-free remission in chronic myeloid leukemia. Leukemia 2016; 30: 1638\u20131647.","journal-title":"Leukemia"},{"key":"BFleu2016360_CR27","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/319675a0","volume":"319","author":"K Karre","year":"1986","unstructured":"Karre K, Ljunggren HG, Piontek G, Kiessling R . Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319: 675\u2013678.","journal-title":"Nature"},{"key":"BFleu2016360_CR28","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/35093109","volume":"413","author":"A Diefenbach","year":"2001","unstructured":"Diefenbach A, Jensen ER, Jamieson AM, Raulet DH . Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001; 413: 165\u2013171.","journal-title":"Nature"},{"key":"BFleu2016360_CR29","doi-asserted-by":"publisher","first-page":"11521","DOI":"10.1073\/pnas.201238598","volume":"98","author":"A Cerwenka","year":"2001","unstructured":"Cerwenka A, Baron JL, Lanier LL . Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 2001; 98: 11521\u201311526.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2016360_CR30","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/leu.2011.239","volume":"26","author":"CI Chen","year":"2012","unstructured":"Chen CI, Koschmieder S, Kerstiens L, Schemionek M, Altvater B, Pscherer S et al. NK cells are dysfunctional in human chronic myelogenous leukemia before and on imatinib treatment and in BCR-ABL-positive mice. Leukemia 2012; 26: 465\u2013474.","journal-title":"Leukemia"},{"key":"BFleu2016360_CR31","doi-asserted-by":"publisher","first-page":"e87794","DOI":"10.1371\/journal.pone.0087794","volume":"9","author":"M Ilander","year":"2014","unstructured":"Ilander M, Kreutzman A, Rohon P, Melo T, Faber E, Porkka K et al. Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-alpha monotherapy. PLoS ONE 2014; 9: e87794.","journal-title":"PLoS ONE"},{"key":"BFleu2016360_CR32","doi-asserted-by":"publisher","first-page":"e23022","DOI":"10.1371\/journal.pone.0023022","volume":"6","author":"A Kreutzman","year":"2011","unstructured":"Kreutzman A, Rohon P, Faber E, Indrak K, Juvonen V, Kairisto V et al. Chronic myeloid leukemia patients in prolonged remission following interferon-alpha monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS ONE 2011; 6: e23022.","journal-title":"PLoS ONE"},{"key":"BFleu2016360_CR33","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1182\/blood-2012-04-425397","volume":"121","author":"R Romee","year":"2013","unstructured":"Romee R, Foley B, Lenvik T, Wang Y, Zhang B, Ankarlo D et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 2013; 121: 3599\u20133608.","journal-title":"Blood"},{"key":"BFleu2016360_CR34","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/ni1138","volume":"5","author":"A Martin-Fontecha","year":"2004","unstructured":"Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004; 5: 1260\u20131265.","journal-title":"Nat Immunol"},{"key":"BFleu2016360_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/ni746","volume":"3","author":"JM Kelly","year":"2002","unstructured":"Kelly JM, Darcy PK, Markby JL, Godfrey DI, Takeda K, Yagita H et al. Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection. Nat Immunol 2002; 3: 83\u201390.","journal-title":"Nat Immunol"},{"key":"BFleu2016360_CR36","doi-asserted-by":"publisher","first-page":"4472","DOI":"10.4049\/jimmunol.168.9.4472","volume":"168","author":"JM Kelly","year":"2002","unstructured":"Kelly JM, Takeda K, Darcy PK, Yagita H, Smyth MJ . A role for IFN-gamma in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo. J Immunol 2002; 168: 4472\u20134479.","journal-title":"J Immunol"},{"key":"BFleu2016360_CR37","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1182\/blood-2011-10-386995","volume":"119","author":"B Foley","year":"2012","unstructured":"Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 2012; 119: 2665\u20132674.","journal-title":"Blood"},{"key":"BFleu2016360_CR38","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nature07665","volume":"457","author":"JC Sun","year":"2009","unstructured":"Sun JC, Beilke JN, Lanier LL . Adaptive immune features of natural killer cells. Nature 2009; 457: 557\u2013561.","journal-title":"Nature"},{"key":"BFleu2016360_CR39","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1084\/jem.20100479","volume":"208","author":"JC Sun","year":"2011","unstructured":"Sun JC, Beilke JN, Bezman NA, Lanier LL . Homeostatic proliferation generates long-lived natural killer cells that respond against viral infection. J Exp Med 2011; 208: 357\u2013368.","journal-title":"J Exp Med"},{"key":"BFleu2016360_CR40","doi-asserted-by":"publisher","first-page":"14725","DOI":"10.1073\/pnas.1110900108","volume":"108","author":"S Lopez-Verges","year":"2011","unstructured":"Lopez-Verges S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York VA et al. Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci USA 2011; 108: 14725\u201314732.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2016360_CR41","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1146\/annurev.immunol.22.012703.104803","volume":"22","author":"GP Dunn","year":"2004","unstructured":"Dunn GP, Old LJ, Schreiber RD . The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329\u2013360.","journal-title":"Annu Rev Immunol"},{"key":"BFleu2016360_CR42","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.1182\/blood-2012-06-437558","volume":"120","author":"N Vey","year":"2012","unstructured":"Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 2012; 120: 4317\u20134323.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/leu2016360.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/leu2016360","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/leu.2016.360","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/leu2016360.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T18:06:38Z","timestamp":1684433198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2016360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,28]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["BFleu2016360"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.360","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,28]]},"assertion":[{"value":"24 August 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"UOS has received honoraria from Ariad. PK has received honoraria from Novartis, BMS, Ariad and Pfizer. HE has received development grant from Novartis and travel grants form BMS and Novartis. HHjH has received honoraria from Novartis, Bristol-Myers Squibb and Ariad. JR has received honoraria and research funding from Novartis and Bristol-Myers Squibb and honoraria from Ariad. SM and KP have received honoraria and research funding from Novartis, Bristol-Myers Squibb, and Pfizer. SM has received research funding from Ariad. The remaning authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}